Antiarrhythmic properties of ranolazine--from bench to bedside.

about

Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine.Put to the test

P2860

Q36360710-3BDEFD65-D7C8-4583-A188-4B80E066C2BE Q42028997-646E80B0-9757-4E6E-A658-5E8BBB4CD5FB

P2860

Antiarrhythmic properties of ranolazine--from bench to bedside.

Item

http://www.wikidata.org/entity/Q39564664

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Antiarrhythmic properties of ranolazine--from bench to bedside.

@en

Antiarrhythmic properties of ranolazine--from bench to bedside.

@nl

type

Item

label

Antiarrhythmic properties of ranolazine--from bench to bedside.

@en

Antiarrhythmic properties of ranolazine--from bench to bedside.

@nl

prefLabel

Antiarrhythmic properties of ranolazine--from bench to bedside.

@en

Antiarrhythmic properties of ranolazine--from bench to bedside.

@nl

P1476

Antiarrhythmic properties of ranolazine--from bench to bedside.

@en

P2093

George Andrikopoulos

http://www.w3.org/2001/XMLSchema#string

Stylianos Tzeis

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.

Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria

Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current

P304

1733-1741

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2012.716826

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22916846

http://www.w3.org/2001/XMLSchema#string

Antiarrhythmic properties of ranolazine--from bench to bedside.

about

P2860

P2860

Antiarrhythmic properties of ranolazine--from bench to bedside.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698